{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edoxaban+60+MG", "query": { "intervention": "Edoxaban 60 MG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edoxaban+60+MG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T18:32:34.911Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01662908", "title": "A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Deep Vein Thrombosis", "Venous Thrombosis" ], "interventions": [ { "name": "edoxaban tosylate", "type": "DRUG" }, { "name": "enoxaparin/unfractionated heparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2012-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 29, "location_summary": "Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01662908" }, { "nct_id": "NCT02073682", "title": "Cancer Venous Thromboembolism (VTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Cancer" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Dalteparin", "type": "DRUG" }, { "name": "Low molecular weight heparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1046, "start_date": "2015-07-16", "completion_date": "2017-09-15", "has_results": true, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 4, "location_summary": "Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more", "locations": [ { "city": "Brandon", "state": "Florida" }, { "city": "Jonesboro", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073682" }, { "nct_id": "NCT02567461", "title": "Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Edoxaban 60 mg", "type": "DRUG" }, { "name": "Edoxaban 30 mg", "type": "DRUG" }, { "name": "Clopidogrel 75 mg", "type": "DRUG" }, { "name": "Aspirin 81 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2016-03", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-04-06", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02567461" }, { "nct_id": "NCT03083704", "title": "A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet alfa (Gen 1 Process 2)", "type": "BIOLOGICAL" }, { "name": "Apixaban 5 MG", "type": "DRUG" }, { "name": "Rivaroxaban 20 MG", "type": "DRUG" }, { "name": "Enoxaparin sodium", "type": "DRUG" }, { "name": "Edoxaban 60 MG", "type": "DRUG" }, { "name": "Andexanet alfa (Gen 2)", "type": "BIOLOGICAL" }, { "name": "Andexanet alfa (Gen 1 Process 3)", "type": "BIOLOGICAL" }, { "name": "Apixaban 10 MG", "type": "DRUG" }, { "name": "Rivaroxaban 10 MG", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 153, "start_date": "2017-02-26", "completion_date": "2017-09-28", "has_results": false, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03083704" }, { "nct_id": "NCT03950076", "title": "EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Intracranial Hemorrhages", "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Non-anticoagulant medical therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Population Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 948, "start_date": "2019-09-20", "completion_date": "2026-07-22", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 10, "location_summary": "Elk Grove Village, Illinois • Lisle, Illinois • New Orleans, Louisiana + 7 more", "locations": [ { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Lisle", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Queens", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950076" }, { "nct_id": "NCT00986154", "title": "Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Thromboembolism", "Venous Thrombosis" ], "interventions": [ { "name": "edoxaban tosylate(DU-176b)", "type": "DRUG" }, { "name": "low molecular weight heparin/unfractionated heparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8292, "start_date": "2009-10", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 82, "location_summary": "Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00986154" }, { "nct_id": "NCT03395639", "title": "Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiac Disease" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Day to 17 Years" }, "enrollment_count": 168, "start_date": "2018-05-15", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03395639" }, { "nct_id": "NCT02943785", "title": "Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban-based Regimen", "type": "DRUG" }, { "name": "VKA-based Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1426, "start_date": "2017-03-21", "completion_date": "2021-02-28", "has_results": true, "last_update_posted_date": "2022-03-24", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02943785" }, { "nct_id": "NCT04593784", "title": "Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ciraparantag", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Point-of-Care Coagulometer (investigational device)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2021-10-13", "completion_date": "2023-08-26", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 3, "location_summary": "South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Secaucus", "state": "New Jersey" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04593784" }, { "nct_id": "NCT02047565", "title": "A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "60mg edoxaban", "type": "DRUG" }, { "name": "180mg edoxaban", "type": "DRUG" }, { "name": "50 IU/kg Beriplex P/N", "type": "DRUG" }, { "name": "25 IU/kg Beriplex P/N", "type": "DRUG" }, { "name": "10 IU/kg Beriplex P/N", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 110, "start_date": "2013-10", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-09-13T18:32:34.911Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047565" } ] }